Relationship between COVID-19 vaccine hesitancy and willingness to pay for the booster dose of COVID-19 vaccine of oncology patients in Taizhou, China

Figures & data

Table 1. Demographic characteristics of the oncology patients (N = 256).

Independent variables	Categories	Total sample, N(%)/Mean ± SD
Total		256 (100%)
Sex	Male	76 (29.7%)
	Female	180 (70.3%)
Age		51.4 ± 12.8
History of allergic reaction to other vaccines	Yes	13 (5.1%)
	No	243 (94.9%)
Comorbidity	Yes	101 (39.5%)
	No	155 (60.5%)
Residence	Rural	160 (62.5%)
	Urban	96 (37.5%)
Education level	Junior high school and below	140 (54.7%)
	High school and above	116 (45.3%)
Occupation	Farmer	97 (37.9%)
	Others	159 (62.1%)
Risk perception of COVID-19	High	64 (25.0%)
	Low	192 (75.0%)
Understanding of COVID-19 vaccine	Very well	31 (12.1%)
	Well	86 (33.6%)
	Relatively moderate	111 (43.4%)
	Unknown	24 (9.4%)
	Not at all	4 (1.6%)
Confidence in the effectiveness of the COVID-19 vaccine	Great	95 (37.1%)
	Relatively great	84 (32.8%)
	Moderate,	74 (28.9%)
	Little	3 (1.2%)
Confidence in the safety of the COVID-19 vaccine	Very safe	60 (23.4%)
	Safe	142 (55.5%)
	Moderate	52 (20.3%)
	Unsafe	2 (0.8%)
	Very unsafe	0 (0%)
COVID-19 vaccine hesitancy	Very hesitant	15 (5.9%)
	Hesitant	114 (44.5%)
	Not hesitant	100 (39.1%)
	Very not hesitant	27 (10.5%)

Figure 1. Distribution of oncology patients’ willingness to pay and the price of the COVID-19 vaccine booster. (A) Distribution of willingness to pay for the booster dose of COVID-19 vaccine (N = 256). (B) Distribution of prices that are acceptable to patients who are willing to pay for the COVID-19 vaccine booster (N = 176).

Figure 2. Relationship between COVID-19 vaccine hesitancy and willingness to pay for the COVID-19 vaccine booster (N = 256).

Table 2. Logistic regression of factors associated with willingness to pay for booster dose of COVID-19 vaccine (N = 256).

Independent variables		Willing to pay vs. unwilling to pay
		cOR (95%CI)	Pc	aOR (95%CI)	Padj
COVID-19 vaccine hesitancy	No vs. yes	3.547 (1.992–6.317)	<0.001	3.040 (1.669–5.540)	<0.001
Understanding of COVID-19 vaccine	High vs. low	1.873 (1.078–3.253)	0.026	1.113 (0.589–2.103)	0.741
Confidence in the effectiveness of the COVID-19 vaccine	High vs. low	2.118 (1.203–3.726)	0.009	1.235 (0.610–2.498)	0.558
Confidence in the safety of the COVID-19 vaccine	High vs. low	2.749 (1.477–5.116)	0.001	1.884 (0.885–4.014)	0.101
Sex	Male vs. female	1.183 (0.653–2.141)	0.579	/	/
Age		1.014 (0.993–1.036)	0.193	/	/
History of allergic reaction to other vaccines	Yes vs. no	0.347 (0.113–1.069)	0.065	/	/
Comorbidity	Yes vs. no	0.953 (0.552–1.644)	0.863	/	/
Education level	Junior high school and below	1.171 (0.685–2.000)	0.564	/	/
	High school and above	1	1	/	/
Residence	Rural vs. urban	1.010 (0.582–1.753)	0.972	/	/
Occupation	Farmer vs. others	0.937 (0.541–1.623)	0.817	/	/
Risk perception of COVID-19	High vs. low	1.558 (0.811–2.992)	0.183	/	/

P_c, cOR (95% CI): unadjusted p-value, crude odds ratio, and 95% confidence interval in univariate binary logistic regression model; P_adj, aOR (95% CI): adjusted p-value, adjusted odds ratio, and 95% confidence interval in multivariate binary logistic regression model, including variables such as COVID-19 vaccine hesitancy, understanding of COVID-19 vaccine, confidence in the effectiveness of the COVID-19 vaccine, and confidence in the safety of the COVID-19 vaccine.

Data availability statement

All data underlying the findings are within the paper.

The data that support the findings of this study are available from the corresponding author, T.H.T, upon reasonable request.